Nanoengineered strategies to optimize dendritic cells for gastrointestinal tumor immunotherapy: From biology to translational medicine

Nanomedicine

Volumn 9, Issue 14, 2014, Pages 2187-2202

  Bhargava, Arpit ^a,b   Bunkar, Neha ^a   Khare, Naveen Kumar ^b   Mishra, Dinesh ^c   Mishra, Pradyumna Kumar ^a,b  

^a DR H S GOUR UNIVERSITY   (India)

^b TATA MEMORIAL HOSPITAL   (India)

^c Institute of Engineering Science   (India)

Author keywords

Cancer therapy; Dendritic cells; Nanomedicine; Translational oncology

Indexed keywords

CANCER VACCINE; CHITOSAN; LIPOSOME; NANOPARTICLE; POLYGLACTIN; SOLID LIPID NANOPARTICLE; TUMOR ANTIGEN;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL TRIAL (TOPIC); CROSS PRESENTATION; DENDRITIC CELL; DIFFUSION; DIGESTIVE SYSTEM CANCER; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MINIMAL RESIDUAL DISEASE; NANOENCAPSULATION; NANOENGINEERING; NANOMEDICINE; NONHUMAN; PROCESS OPTIMIZATION; REVIEW; SUSTAINED DRUG RELEASE; T LYMPHOCYTE; TRANSLATIONAL RESEARCH; TUMOR MICROENVIRONMENT; GASTROINTESTINAL NEOPLASMS; IMMUNOTHERAPY; NANOTECHNOLOGY;

CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; NANOTECHNOLOGY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84911500818     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/NNM.14.115     Document Type: Review

References (148)

1. Li W, Zhang X, Zhou M et al. Functional core/shell drug nanoparticles for highly effective synergistic cancer therapy. Adv. Healthc. Mater. 3, 1475-1485 (2014).
2. Golla K, Bhaskar C, Ahmed F, Kondapi AK. A target-specific oral formulation of doxorubicin-protein nanoparticles: efficacy and safety in hepatocellular cancer. J. Cancer 4, 644-652 (2013).
3. Bhargava A, Mishra D, Khan S, Varshney SK, Banerjee S, Mishra PK. Assessment of tumor antigen-loaded solid lipid nanoparticles as an efficient delivery system for dendritic cell engineering. Nanomedicine (Lond.) 8, 1067-1084 (2013).
4. Prasad S, Cody V, Saucier-Sawyer JK et al. Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy. Nanomedicine 7, 1-10 (2011).
5. Bray F, Ren JS, Masuyer E, Ferlay J. Estimates of global cancer prevalence for 27 sites in the adult population in 2008. Int. J. Cancer 132, 1133-1145 (2013).
6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide: IARC Cancer Base No. 10. International Agency for Research on Cancer, France (2010). http://globocan.iarc.fr
7. Cervera P, Fléjou JF. Changing pathology with changing drugs: tumors of the gastrointestinal tract. Pathobiology 78, 76-89 (2011).
8. Poglio S, Galvani S, Bour S et al. Adipose tissue sensitivity to radiation exposure. Am. J. Pathol. 174, 44-53 (2009).
9. Homayounfar K, Bleckmann A, Conradi LC et al. Bilobar spreading of colorectal liver metastases does not significantly affect survival after R0 resection in the era of interdisciplinary multimodal treatment. Int. J. Colorectal Dis. 27, 1359-1367 (2012).
10. Baeten CI, Castermans K, Lammering G et al. Effects of radiotherapy and chemotherapy on angiogenesis and leukocyte infiltration in rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 66, 1219-1227 (2006).
11. Prestwich RJ, Errington F, Hatfield P et al. The immune system - is it relevant to cancer development, progression and treatment? Clin. Oncol. (R. Coll. Radiol.) 20, 101-112 (2008).
12. Bhargava A, Mishra D, Banerjee S, Mishra PK. Engineered dendritic cells for gastrointestinal tumor immunotherapy: opportunities in translational research. J. Drug Target. 21, 126-136 (2013).
13. Li H, Li Y, Jiao J, Hu HM. Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nat. Nanotechnol. 6, 645-650 (2011).
14. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 66, 2873-2896 (2009).
15. Busman-Sahay K, Sargent E, Harton JA, Drake JR. The Ia.2 epitope defines a subset of lipid raft-resident MHC class II molecules crucial to effective antigen presentation. J. Immunol. 186, 6710-6717 (2011).
16. Fritzsche S, Springer S. Investigating MHC class I folding and trafficking with pulse-chase experiments. Mol. Immunol. 55, 126-130 (2013).
17. Dauer M, Obermaier B, Herten J et al. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J. Immunol. 170, 4069-4076 (2003)
18. + monocytes to generate dendritic cells for cancer immunotherapy: a Phase I study. J. Hematother. Stem Cell Res. 12, 515-523 (2003).
19. Galetto A, Contarini M, Sapino A et al. Ex vivo host response to gastrointestinal cancer cells presented by autologous dendritic cells. J. Surg. Res. 100, 32-38 (2001).
20. + cells. Transfusion 49, 2109-2121 (2009).
21. Higgins JP, Bernstein MB, Hodge JW. Enhancing immune responses to tumor-associated antigens. Cancer Biol. Ther. 8, 1440-1449 (2009).
22. Pejawar-Gaddy S, Rajawat Y, Hilioti Z et al. Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunol. Immunother. 59, 1685-1696 (2010).
23. Kamata Y, Kuhara A, Iwamoto T et al. Identification of HLA class I-binding peptides derived from unique cancer-associated proteins by mass spectrometric analysis. Anticancer Res. 33, 1853-1859 (2013).
24. Kreiter S, Selmi A, Diken M et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 70, 9031-9040 (2010).
25. Ying M, Zhen Q, Liu S, Gong F, Xie Y. Treatment of established colon carcinoma-bearing mice by dendritic cells pulsed with lysates of heat-treated tumor cells. Sci. China C. Life Sci. 52, 831-835 (2009).
26. Brusa D, Garetto S, Chiorino G et al. Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity. Vaccine 26, 6422-6432 (2008).
27. Tobiásová Z, Pospísilová D, Miller AM et al. In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients. Clin. Immunol. 122, 18-27 (2007).
28. Schott M, Feldkamp J, Lettmann M, Simon D, Scherbaum WA, Seissler J. Dendritic cell immunotherapy in a neuroendocrine pancreas carcinoma. Clin. Endocrinol. (Oxf.) 55, 271-277 (2001).
29. Barth RJ Jr, Fisher DA, Wallace PK et al. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin. Cancer Res. 16, 5548-5556 (2010).
30. Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum. Immunol. 65, 794-802 (2004).
31. Hatfield P, Merrick AE, West E et al. Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. J. Immunother. 31, 620-632 (2008).
32. Hoos A, Parmiani G, Hege K et al. A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. 30, 1-15 (2007).
33. + T cells. Blood 116, 4501-4511 (2010).
34. Ojima T, Iwahashi M, Nakamura M et al. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice. Int. J. Cancer 120, 585-593 (2007).
35. Rossowska J, Pajtasz-Piasecka E, Rysnik O et al. Generation of antitumor response by IL-2-transduced JAWS II dendritic cells. Immunobiology 216, 1074-1084 (2011).
36. Murthy V, Moiyadi A, Sawant R, Sarin R. Clinical considerations in developing dendritic cell vaccine based immunotherapy protocols in cancer. Curr. Mol. Med. 9, 725-731 (2009).
37. Burgdorf SK, Fischer A, Myschetzky PS et al. Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. Oncol. Rep. 20, 1305-1311 (2008).
38. Burgdorf SK. Dendritic cell vaccination of patients with metastatic colorectal cancer. Dan. Med. Bull. 57, B4171 (2010).
39. Lesterhuis WJ, de Vries IJ, Schuurhuis DH et al. Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Ann. Oncol. 17, 974-980 (2006).
40. Onishi H, Morisaki T, Baba E et al. Long-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma. Anticancer Res. 31, 3995-4005 (2011).
41. Liu KJ, Wang CC, Chen LT et al. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A∗0201 and HLA-A∗2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin. Cancer Res. 10, 2645-2651 (2004).
42. Tamir A, Basagila E, Kagahzian A et al. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. Cancer Immunol. Immunother. 56, 2003-2016 (2007).
43. Morse MA, Nair SK, Mosca PJ et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest. 21, 341-349 (2003).
44. Lesterhuis WJ, De Vries IJ, Schreibelt G et al. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res. 30, 5091-5097 (2010).
45. Morse MA, Clay TM, Hobeika AC et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin. Cancer Res. 11, 3017-3024 (2005).
46. Babatz J, Röllig C, Löbel B et al. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol. Immunother. 55, 268-276 (2006).
47. Kavanagh B, Ko A, Venook A et al. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J. Immunother. 30, 762-772 (2007).
48. Lesterhuis WJ, de Vries IJ, Aarntzen EA et al. A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. Br. J. Cancer 103, 1415-1421 (2010).
49. Toh HC, Wang WW, Chia WK et al. Clinical benefit of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in MAGE-positive colorectal cancer patients. Clin. Cancer Res. 15, 7726-7736 (2009).
50. Lepisto AJ, Moser AJ, Zeh H et al. A Phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 6, 955-964 (2008).
51. Rong Y, Qin X, Jin D et al. A Phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Clin. Exp. Med. 12, 173-180 (2011).
52. Pecher G, Häring A, Kaiser L, Thiel E. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a Phase I/II clinical trial. Cancer Immunol. Immunother. 51, 669-673 (2002).
53. Suso EM, Dueland S, Rasmussen AM et al. hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol. Immunother. 60, 809-818 (2011).
54. Nakamura I, Kanazawa M, Sato Y et al. Clinical evaluation of dendritic cells vaccination for advanced cancer patients at Fukushima Medical University. Fukushima J. Med. Sci. 58, 40-48 (2012).
55. Nakamura M, Wada J, Suzuki H, Tanaka M, Katano M, Morisaki T. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer. Anticancer Res. 29, 831-836 (2009).
56. Bauer C, Dauer M, Saraj S et al. Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study. Cancer Immunol. Immunother. 60, 1097-1107 (2011).
57. Kimura Y, Tsukada J, Tomoda T et al. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas 41, 195-205 (2012).
58. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J. Immunother. 28, 496-504 (2005).
59. Gao J, Chen M, Ren H. [Clinical effects of dendritic cells pulsed with autologous hepatoma cell lysates on the postoperative recurrence and metastasis of hepatocellular carcinoma]. Zhonghua Gan Zang Bing Za Zhi 13, 432-435 (2005).
60. Palmer DH, Midgley RS, Mirza N et al. A Phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 49, 124-132 (2009).
61. Chi KH, Liu SJ, Li CP et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J. Immunother. 28, 129-135 (2005).
62. Kono K, Takahashi A, Sugai H et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin. Cancer Res. 8, 3394-3400 (2002).
63. Sadanaga N, Nagashima H, Mashino K et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin. Cancer Res. 7, 2277-2284 (2001).
64. Fujiwara S, Wada H, Miyata H et al. Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer. J. Immunother. 35, 513-521 (2012).
65. Khan JA, Yaqin S. Successful immunological treatment of gallbladder cancer in India - case report. J. Zhejiang Univ. Sci. B 7, 719-724 (2006).
66. Sun NF, Meng QY, Tian AL et al. Nanoliposome-mediated FL/TRAIL double-gene therapy for colon cancer: in vitro and in vivo evaluation. Cancer Lett. 315, 69-77 (2012).
67. Huang FP, Chen YX, To CK. Guiding the 'misguided' - functional conditioning of dendritic cells for the DC-based immunotherapy against tumours. Eur. J. Immunol. 41, 18-25 (2011).
68. Bianchi G, Borgonovo G, Pistoia V, Raffaghello L. Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells. Histol. Histopathol. 26, 941-951 (2011).
69. Janikashvili N, Bonnotte B, Katsanis E, Larmonier N. The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin. Dev. Immunol. 2011, 430394 (2011).
70. + regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin. Cancer Res. 13, 902-911 (2007).
71. Muthuswamy R, Urban J, Lee JJ, Reinhart TA, Bartlett D, Kalinski P. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res. 68, 5972-5978 (2008).
72. Munn DH, Sharma MD, Baban B et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22, 633-642 (2005).
73. Saito H, Tsujitani S, Ikeguchi M, Maeta M, Kaibara N. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br. J. Cancer 78, 1573-1577 (1998).
74. Ananiev J, Gulubova MV, Manolova IM. Prognostic significance of CD83 positive tumor-infiltrating dendritic cells and expression of TGF-beta 1 in human gastric cancer. Hepatogastroenterology 58, 1834e40 (2011).
75. Aoe T, Saito T. Activated macrophages induces structural abnormalities of the T cell receptor-CD3 complex. J. Exp. Med. 181, 1881-1886 (1995).
76. Dong R, Moulding D, Himoudi N et al. Cells with dendritic cell morphology and immunophenotype, binuclear morphology, and immunosuppressive function in dendritic cell cultures. Cell Immunol. 272, 1-10 (2011).
77. Zhang Z, Guo Y, Feng S. Nanoimmunotherapy: application of nanotechnology for sustained and targeted delivery of antigens to dendritic cells. Nanomedicine (Lond.) 7, 1-4 (2012).
78. Mishra D, Mishra PK, Dabadghao S et al. Comparative evaluation of hepatitis B surface antigen-loaded elastic liposomes and ethosomes for human dendritic cell uptake and immune response. Nanomedicine 6, 110-118 (2010).
79. Mishra D, Mishra PK, Dubey V, Nahar M, Dabadghao S, Jain NK. Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigen-loaded modified liposomes. Eur. J. Pharm. Sci. 33, 424-433 (2008).
80. Li J, Ni X, Zhou Z, Leong KW. Preparation and characterization of polypseudorotaxanes based on block-selected inclusion complexation between poly(propylene oxide)-poly(ethylene oxide)-poly(propylene oxide) triblock copolymers and alpha-cyclodextrin. J. Am. Chem. Soc. 125, 1788-1795 (2003).
81. Zhao L, Seth A, Wibowo N et al. Nanoparticle vaccines. Vaccine 32, 327-337 (2014).
82. Lewis DH. Controlled release of bioactive agents from lactide/glycolide polymers. In: Biodegradable Polymers as Drug Delivery Systems. Chasin M, Langer R (Eds). Marcel Dekker, New York, USA, 1-43 (1990).
83. Joshi VB, Geary SM, Salem AK. Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses. Hum. Vaccin. Immunother. 9, 2584-2590 (2013).
84. Liu M, Li H, Luo G, Liu Q, Wang Y. Pharmacokinetics and biodistribution of surface modification polymeric nanoparticles. Arch. Pharm. Res. 31, 547-554 (2008).
85. Schliehe C, Schliehe C, Thiry M et al. Microencapsulation of inorganic nanocrystals into PLGA microsphere vaccines enables their intracellular localization in dendritic cells by electron and fluorescence microscopy. J. Control. Release 151, 278-285 (2011).
86. Xiang SD, Scholzen A, Minigo G et al. Pathogen recognition and development of particulate vaccines: does size matter? Methods 40, 1-9 (2006).
87. Thomann-Harwood LJ, Kaeuper P, Rossi N, Milona P, Herrmann B, McCullough KC. Nanogel vaccines targeting dendritic cells: contributions of the surface decoration and vaccine cargo on cell targeting and activation. J. Control. Release 166, 95-105 (2013).
88. Uto T, Akagi T, Toyama M et al. Comparative activity of biodegradable nanoparticles with aluminum adjuvants: antigen uptake by dendritic cells and induction of immune response in mice. Immunol. Lett. 140, 36-43 (2011).
89. Rice-Ficht AC, Arenas-Gamboa AM, Kahl-McDonagh MM, Ficht TA. Polymeric particles in vaccine delivery. Curr. Opin. Microbiol. 13, 106-112 (2009).
90. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control. Release 112, 26-34 (2006).
91. Mottram PL, Leong D, Crimeen-Irwin B et al. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol. Pharm. 4, 73-84 (2007).
92. Kulkarni SA, Feng SS. Surface functionalized nanoparticles of biodegradable polymers for targeted delivery of diagnostic and therapeutic agents across the blood-brain barrier (BBB). Nanomedicine (Lond.) 6, 377-394 (2011).
93. Mohanan D, Slütter B, Henriksen-Lacey M et al. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J. Control. Release 147, 342-349 (2010).
94. Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int. J. Pharm. 298, 315-322 (2005).
95. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38, 1404-1413 (2008).
96. Reddy LH, Arias JL, Nicolas J, Couvreur P. Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem. Rev. 112, 5818-5878 (2012).
97. Wischke C, Borchert HH, Zimmermann J, Siebenbrodt I, Lorenzen DR. Stable cationic microparticles for enhanced model antigen delivery to dendritic cells. J. Control. Release 114, 359-368 (2006).
98. Ma Y, Zhuang Y, Xie X et al. The role of surface charge density in cationic liposome-promoted dendritic cell maturation and vaccine-induced immune responses. Nanoscale 3, 2307-2314 (2011).
99. Mou Y, Chen B, Zhang Y et al. Influence of synthetic superparamagnetic iron oxide on dendritic cells. Int. J. Nanomedicine 6, 1779-1786 (2011).
100. Florez, L, Herrmann C, Cramer JM. How shape influences uptake: interactions of anisotropic polymer nanoparticles and human mesenchymal stem cells. Small 8, 2222-2230 (2012).
101. Kourtis IC, Hirosue S, de Titta A et al. Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. PLoS ONE 8, e61646 (2013).
102. Gilboa E. DC-based cancer vaccines. J. Clin. Invest. 117, 1195-1203 (2007).
103. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 449, 419-426 (2007).
104. Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond.) 6, 715-728 (2011).
105. Tel J, Sittig SP, Blom RA et al. Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J. Immunol. 191, 5005-5012 (2013).
106. Idoyaga J, Lubkin A, Fiorese C et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within anti-bodies to Langerin, DEC205, and Clec9A. Proc. Natl Acad. Sci. USA 108, 2384-2389 (2011).
107. - dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192, 1685-1696 (2000).
108. Wang C, Ge Q, Ting D et al. Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat. Mater. 3, 190-196 (2004).
109. + T cell tolerance. Immunity 18, 713-720 (2003).
110. Sixt M, Kanazawa N, Selg M et al. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity 22, 19-29 (2005).
111. Chen L, Chen Q, Zhuang Z et al. Effect of the weekly administration of liposome-paclitaxel combined with s-1 on advanced gastric cancer. Jpn J. Clin. Oncol. 44, 208-213 (2014).
112. Xu X, Wang L, Xu HQ, Huang XE, Qian YD, Xiang J. Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac. J. Cancer Prev. 14, 2591-2594 (2013).
113. Adiseshaiah PP, Clogston JD, McLeland CB et al. Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models. Cancer Lett. 337, 254-265 (2013).
114. Perche F, Benvegnu T, Berchel M et al. Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomedicine 7, 445-453 (2011).
115. Li L, Xiang D, Shigdar S et al. Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells. Int. J. Nanomedicine 9, 1083-1096 (2014).
116. Yin P, Wang Y, Qiu Y et al. Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity. Int. J. Nanomedicine 7, 3961-3969 (2012).
117. Brinkhoff B, Ostroumov D, Heemcke J et al. Microsphere priming facilitates induction of potent therapeutic T-cell immune responses against autochthonous liver cancers. Eur. J. Immunol. 44, 1213-1224 (2013).
118. Venkatesan P, Puvvada N, Dash R et al. The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer. Biomaterials 32, 3794-3806 (2011).
119. Madhavi M, Madhavi K, Jithan AV. Preparation and in vitro /in vivo characterization of curcumin microspheres intended to treat colon cancer. J. Pharm. Bioallied Sci. 4, 164-171 (2012).
120. Xu Q, Leong J, Chua QY et al. Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma. Biomaterials 34, 5149-5162 (2013).
121. Li C, Zhang Y, Zhou J, Zhao G, Tang S. Therapeutic effect and tolerability of gelatin sponge particle-mediated chemoembolization for colorectal liver metastases: a retrospective study. World J. Surg. Oncol. 11, 222 (2013).
122. Jaiswal M, Naz F, Dinda AK, Koul V. In vitro and in vivo efficacy of doxorubicin loaded biodegradable semi-interpenetrating hydrogel implants of poly (acrylic acid)/gelatin for post surgical tumor treatment. Biomed. Mater. 8, 045004 (2013).
123. Coester C, Nayyar P, Samuel J. In vitro uptake of gelatin nanoparticles by murine dendritic cells and their intracellular localisation. Eur. J. Pharm. Biopharm. 62, 306-314 (2006).
124. Yin HT, Zhang DG, Wu XL, Huang XE, Chen G. In vivo evaluation of curcumin-loaded nanoparticles in a A549 xenograft mice model. Asian Pac. J. Cancer Prev. 14, 409-412 (2013).
125. Ortiz R, Prados J, Melguizo C et al. 5-fluorouracil-loaded poly(e-caprolactone) nanoparticles combined with phage E gene therapy as a new strategy against colon cancer. Int. J. Nanomedicine 7, 95-107 (2012).
126. Dominguez AL, Lustgarten J. Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses. Vaccine 28, 1383-1390 (2010).
127. Araki T, Kono Y, Ogawara K et al. Formulation and evaluation of paclitaxel-loaded polymeric nanoparticles composed of polyethylene glycol and polylactic acid block copolymer. Biol. Pharm. Bull. 35, 1306-1313 (2012).
128. Eby JK, Dane KY, O'Neil CP, Hirosue S, Swartz MA, Hubbell JA. Polymer micelles with pyridyl disulfide-coupled antigen travel through lymphatics and show enhanced cellular responses following immunization. Acta Biomater. 8, 3210-3217 (2012).
129. Uto T, Toyama M, Nishi Y et al. Uptake of biodegradable poly(g-glutamic acid) nanoparticles and antigen presentation by dendritic cells in vivo. Results Immunol. 3, 1-9 (2012).
130. Yamaguchi S, Tatsumi T, Takehara T et al. EphA2-derived peptide vaccine with amphiphilic poly(gamma-glutamic acid) nanoparticles elicits an anti-tumor effect against mouse liver tumor. Cancer Immunol. Immunother. 59, 759-767 (2010).
131. Zhu R, Wu X, Xiao Y et al. Synergetic effect of SLN-curcumin and LDH-5-Fu on SMMC-7721 liver cancer cell line. Cancer Biother. Radiopharm. 28, 579-587 (2013).
132. Minelli R, Serpe L, Pettazzoni P et al. Cholesteryl butyrate solid lipid nanoparticles inhibit the adhesion and migration of colon cancer cells. Br. J. Pharmacol. 166, 587-601 (2012).
133. Chen D, Koropatnick J, Jiang N et al. Targeted siRNA silencing of indoleamine 2, 3-dioxygenase in antigen-presenting cells using mannose-conjugated liposomes: a novel strategy for treatment of melanoma. J. Immunother. 37, 123-134 (2014).
134. Wang C, Zhuang Y, Zhang Y et al. Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells. Vaccine 30, 4790-4799 (2012).
135. van Broekhoven CL, Parish CR, Demangel C, Britton WJ, Altin JG. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res. 64, 4357-4365 (2004).
136. + T-cell responses by targeting DC-SIGN ondendritic cells. J. Control. Release 160, 88-95 (2012).
137. Cruz LJ, Rueda F, Cordobilla B et al. Targeting nanosystems to human DCs via Fc receptor as an effective strategy to deliver antigen for immunotherapy. Mol. Pharm. 8, 104-116 (2011).
138. Cruz LJ, Rueda F, Simón L, Cordobilla B, Albericio F, Domingo J. Liposomes containing NY-ESO-1/tetanus toxoid and adjuvant peptides targeted to human dendritic cells via the Fc receptor for cancer vaccines. Nanomedicine (Lond.) 9, 435-449 (2014).
139. Lee YR, Lee YH, Kim KH, Im SA, Lee CK. Induction of potent antigen-specific cytotoxic T cell response by PLGA-nanoparticles containing antigen and TLR agonist. Immune Netw. 13, 30-33 (2013).
140. Ma W, Smith T, Bogin V et al. Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy. J. Transl. Med. 9, 34 (2011).
141. Hamdy S, Haddadi A, Hung RW, Lavasanifar A. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv. Drug Deliv. Rev. 63, 943-955 (2011).
142. Clawson C, Huang CT, Futalan D et al. Delivery of a peptide via poly(d, l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity. Nanomedicine 6, 651-661 (2010).
143. Cruz LJ, Tacken PJ, Rueda F, Domingo JC, Albericio F, Figdor CG. Targeting nanoparticles to dendritic cells for immunotherapy. Methods Enzymol. 509, 143-163 (2012).
144. Mishra H, Mishra D, Mishra PK, Nahar M, Dubey V, Jain NK. Evaluation of solid lipid nanoparticles as carriers for delivery of hepatitis B surface antigen for vaccination using subcutaneous route. J. Pharm. Pharm. Sci. 13, 495-509 (2010).
145. Bondì ML, Craparo EF, Giammona G, Drago F. Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution. Nanomedicine (Lond.) 5, 25-32 (2010).
146. Tan G, Wang Z, Zhang X, Cai Z, Zhang J. Induction of CTLs by DCs pulsed with K-ras mutant peptide on the surface of nanoparticles in the treatment of pancreatic cancer. Oncol. Rep. 26, 215-221 (2011).
147. Mou Y, Hou Y, Chen B et al. In vivo migration of dendritic cells labeled with synthetic superparamagnetic iron oxide. Int. J. Nanomedicine 6, 2633-2640 (2011).
148. Tavaré R, Sagoo P, Varama G et al. Monitoring of in vivo function of superparamagnetic iron oxide labelled murine dendritic cells during anti-tumour vaccination. PLoS ONE 6, e19662 (2011).